Cargando…

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

INTRODUCTION: We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to evaluate the association between TIR and endothelial injury in patients with type 2 diabetes mellitus (T2DM). METHODS: Two-hundred patients with T2DM tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Yunyi, Yang, Kun, Yang, Jin, Fu, Wei, Xiao, Wenhua, Wei, Rui, Hong, Tianpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500125/
https://www.ncbi.nlm.nih.gov/pubmed/35963931
http://dx.doi.org/10.1007/s13300-022-01310-3
_version_ 1784795144231321600
author Le, Yunyi
Yang, Kun
Yang, Jin
Fu, Wei
Xiao, Wenhua
Wei, Rui
Hong, Tianpei
author_facet Le, Yunyi
Yang, Kun
Yang, Jin
Fu, Wei
Xiao, Wenhua
Wei, Rui
Hong, Tianpei
author_sort Le, Yunyi
collection PubMed
description INTRODUCTION: We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to evaluate the association between TIR and endothelial injury in patients with type 2 diabetes mellitus (T2DM). METHODS: Two-hundred patients with T2DM treated with exenatide for 16 weeks were included in this study. Seven-point fingerstick blood glucose was used to evaluate derived TIR and glycemic variability. The serum levels of soluble endothelial cell protein C receptor (sEPCR) and von Willebrand factor (vWF) were measured. Ninety-three patients having the data of endothelial injury markers were categorized as derived TIR > 70% or ≤ 70% after the treatment and the association between TIR and endothelial injury were evaluated. RESULTS: Treatment with exenatide for 16 weeks resulted in a significant reduction in fasting blood glucose, postprandial 2 h blood glucose, and glycated hemoglobin A1c (HbA1c) levels in patients with T2DM. Compared with baseline, derived TIR value was significantly increased [85.7 (57.1, 100.0) % vs. 42.9 (14.9, 71.4) %, P < 0.001], and the parameters of glycemic variability were remarkably decreased after the treatment. After the treatment, serum sEPCR level was significantly decreased from baseline in patients with TIR > 70% [74.5 (32.8, 122.5) ng/mL vs. 96.9 (48.5, 150.9) ng/mL, P = 0.006] but not in those with TIR ≤ 70%; serum vWF level was remarkably decreased in patients with TIR > 70% [from 1166.2 (848.1, 1335.5) mIU/mL to 907.4 (674.3, 1335.1) mIU/mL, P = 0.001] while this effect was modest in those with TIR ≤ 70%. CONCLUSIONS: Treatment with exenatide increases TIR and decreases glycemic variability in patients with T2DM. Moreover, the amelioration of endothelial injury is more pronounced in patients with TIR > 70% after the treatment. TRIAL REGISTRATION: ChiCTR-IPR-15006558 (registered, 27 May 2015). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-022-01310-3.
format Online
Article
Text
id pubmed-9500125
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-95001252022-09-24 Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide Le, Yunyi Yang, Kun Yang, Jin Fu, Wei Xiao, Wenhua Wei, Rui Hong, Tianpei Diabetes Ther Original Research INTRODUCTION: We aimed to investigate whether treatment with exenatide could increase time in range (TIR) and decrease glycemic variability, and to evaluate the association between TIR and endothelial injury in patients with type 2 diabetes mellitus (T2DM). METHODS: Two-hundred patients with T2DM treated with exenatide for 16 weeks were included in this study. Seven-point fingerstick blood glucose was used to evaluate derived TIR and glycemic variability. The serum levels of soluble endothelial cell protein C receptor (sEPCR) and von Willebrand factor (vWF) were measured. Ninety-three patients having the data of endothelial injury markers were categorized as derived TIR > 70% or ≤ 70% after the treatment and the association between TIR and endothelial injury were evaluated. RESULTS: Treatment with exenatide for 16 weeks resulted in a significant reduction in fasting blood glucose, postprandial 2 h blood glucose, and glycated hemoglobin A1c (HbA1c) levels in patients with T2DM. Compared with baseline, derived TIR value was significantly increased [85.7 (57.1, 100.0) % vs. 42.9 (14.9, 71.4) %, P < 0.001], and the parameters of glycemic variability were remarkably decreased after the treatment. After the treatment, serum sEPCR level was significantly decreased from baseline in patients with TIR > 70% [74.5 (32.8, 122.5) ng/mL vs. 96.9 (48.5, 150.9) ng/mL, P = 0.006] but not in those with TIR ≤ 70%; serum vWF level was remarkably decreased in patients with TIR > 70% [from 1166.2 (848.1, 1335.5) mIU/mL to 907.4 (674.3, 1335.1) mIU/mL, P = 0.001] while this effect was modest in those with TIR ≤ 70%. CONCLUSIONS: Treatment with exenatide increases TIR and decreases glycemic variability in patients with T2DM. Moreover, the amelioration of endothelial injury is more pronounced in patients with TIR > 70% after the treatment. TRIAL REGISTRATION: ChiCTR-IPR-15006558 (registered, 27 May 2015). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-022-01310-3. Springer Healthcare 2022-08-13 2022-10 /pmc/articles/PMC9500125/ /pubmed/35963931 http://dx.doi.org/10.1007/s13300-022-01310-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Le, Yunyi
Yang, Kun
Yang, Jin
Fu, Wei
Xiao, Wenhua
Wei, Rui
Hong, Tianpei
Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title_full Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title_fullStr Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title_full_unstemmed Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title_short Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide
title_sort association of time in range with endothelial injury in patients with type 2 diabetes treated with exenatide
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500125/
https://www.ncbi.nlm.nih.gov/pubmed/35963931
http://dx.doi.org/10.1007/s13300-022-01310-3
work_keys_str_mv AT leyunyi associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT yangkun associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT yangjin associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT fuwei associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT xiaowenhua associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT weirui associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide
AT hongtianpei associationoftimeinrangewithendothelialinjuryinpatientswithtype2diabetestreatedwithexenatide